---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-003519"
form_type: "8-K"
ticker: "ZYME"
cik: "0001937653"
company_name: "Zymeworks Inc."
filed_at: "2025-01-08T23:59:59+00:00"
generated_at: "2026-05-28T07:16:05.521908+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Zymeworks reports $324M cash, provides 2025-2026 pipeline milestones and cash runway into 2H-2027

## Summary
- Cash resources ~$324M as of Dec 31, 2024, plus $25M milestone from Jazz expected in Q1 2025.
- Cash runway expected to fund planned operations into 2H-2027, including anticipated regulatory milestone payments.
- Phase 3 HERIZON-GEA-01 top-line results for zanidatamab in first-line GEA expected 2Q 2025; sBLA later in 2025.
- Potential EU approval for zanidatamab in second-line BTC as early as 2Q 2025; China NMPA decision as early as 2H 2025.
- IND applications for ZW220, ZW251 in solid tumors in 2025; ZW209 and ZW1528 (AIID) INDs in 2026.

## SEC filing metadata
- accession: 0001193125-25-003519
- form_type: 8-K
- ticker: ZYME
- cik: 0001937653
- company_name: Zymeworks Inc.
- filed_at: 2025-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937653/000119312525003519/0001193125-25-003519-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937653/000119312525003519/d894323d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-003519
- JSON: https://secwatch.observer/filing/0001193125-25-003519.json
- Plain text: https://secwatch.observer/filing/0001193125-25-003519.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.